PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
70.18%
Revenue growth above 1.5x CSIQ's 20.03%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
111.14%
Gross profit growth above 1.5x CSIQ's 17.92%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
444.77%
EBIT growth above 1.5x CSIQ's 38.07%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
1553.08%
Operating income growth above 1.5x CSIQ's 5.30%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
656.87%
Net income growth above 1.5x CSIQ's 25.69%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
580.95%
EPS growth above 1.5x CSIQ's 27.66%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
580.95%
Diluted EPS growth above 1.5x CSIQ's 27.66%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.19%
Share reduction while CSIQ is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
0.05%
Slight or no buyback while CSIQ is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
946.34%
OCF growth of 946.34% while CSIQ is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
792.23%
FCF growth of 792.23% while CSIQ is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
12104.02%
Similar 10Y revenue/share CAGR to CSIQ's 11794.02%. Walter Schloss might see both firms benefiting from the same long-term demand.
678.10%
5Y revenue/share CAGR under 50% of CSIQ's 6186.44%. Michael Burry would suspect a significant competitive gap or product weakness.
229.29%
3Y revenue/share CAGR above 1.5x CSIQ's 126.11%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
11014.38%
OCF/share CAGR of 11014.38% while CSIQ is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
70160.74%
OCF/share CAGR of 70160.74% while CSIQ is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
820.71%
3Y OCF/share CAGR above 1.5x CSIQ's 53.59%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
1219.73%
Below 50% of CSIQ's 4360.68%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
5895.86%
5Y net income/share CAGR above 1.5x CSIQ's 1608.14%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
2361.57%
3Y net income/share CAGR above 1.5x CSIQ's 171.29%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
56.12%
Below 50% of CSIQ's 4778.50%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
51.21%
Below 50% of CSIQ's 169.39%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
76.95%
AR growth well above CSIQ's 17.00%. Michael Burry fears inflated revenue or higher default risk in the near future.
9.65%
Inventory shrinking or stable vs. CSIQ's 38.53%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
16.18%
Asset growth above 1.5x CSIQ's 1.53%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
16.24%
BV/share growth above 1.5x CSIQ's 6.55%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
43.49%
We have some new debt while CSIQ reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
5.33%
R&D dropping or stable vs. CSIQ's 64.35%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
53.53%
SG&A growth well above CSIQ's 36.49%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.